Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease.

CONCLUSIONS: Combined assessment of serum αSyn and Rab35 is a better biomarker for discriminating PD patients from NC or atypical parkinsonian patients, and is a useful predictive biomarker for younger sporadic PD patients. PMID: 31591837 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/31591837?dopt=Abstract

Source: Journal of Clinical Neurology - October 9, 2019 Category: Neurology Tags: J Clin Neurol Source Type: research

More News: Brain | Neurology | Parkinson's Disease | Progressive Supranuclear Palsy